...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)　– Multicenter Retrospective Cohort Study in Japan –
【24h】

Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)　– Multicenter Retrospective Cohort Study in Japan –

机译：非维生素K拮抗剂口服抗凝剂（NOACs）引起的颅内出血He –日本多中心回顾性队列研究–

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: We conducted a multicenter retrospective cohort study to elucidate the characteristics of intracranial hemorrhage (ICH) in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants (NOACs). Methods?and?Results: We sent a questionnaire to the directors of 241 stroke centers in Japan to establish the clinical characteristics of NOAC-associated cerebral hemorrhage (CH), including hematoma size, hematoma enlargement (HE) and in-hospital mortality of patients treated in their institutions. We undertook a literature review to establish the clinical characteristics of warfarin-associated CH and compared these with our data. We received 174 responses (72.2%), of which 67 (38.5%) gave anonymous details of 130 eligible patients (male, 67.7%; mean age, 77.3±8.3 years, in-hospital mortality rate, 11.5%). We judged that 87 of the 130 patients had presented with CH: one-fifth had taken antiplatelet drugs. We found that the incidences of HE and mortality in the 87 patients presenting with NOAC-associated CH were lower than would have been expected in those with warfarin-associated CH (17% vs. 26%, and 16% vs. 35%, respectively). Conclusions: More than half the stroke center directors who responded to our questionnaire had not experienced cases of NOAC-associated ICH. Compared with warfarin, NOACs appear to present a lower risk of HE and death in patients with atrial fibrillation who develop CH. ( Circ J 2015; 79: 1018–1023)
机译：背景：我们进行了一项多中心回顾性队列研究，以阐明接受非维生素K拮抗剂口服抗凝剂（NOAC）治疗的房颤患者颅内出血（ICH）的特征。方法和结果：我们向日本的241个中风中心的负责人发送了一份调查问卷，以确定与NOAC相关的脑出血（CH）的临床特征，包括血肿大小，血肿扩大（HE）和患者住院死亡率在他们的机构中​​接受治疗。我们进行了文献综述，以建立华法林相关CH的临床特征，并将其与我们的数据进行比较。我们收到174份答复（72.2％），其中67份（38.5％）匿名记录了130名合格患者的病历（男性为67.7％;平均年龄为77.3±8.3岁，院内死亡率为11.5％）。我们判断130例患者中有87例患有CH：五分之一服用了抗血小板药物。我们发现，与NOAC相关的CH出现的87例患者中，HE的发生率和死亡率低于华法林相关的CH（分别为17％对26％和16％对35％）。 ）。结论：回答我们问卷的中风中心主任中有一半以上没有经历过NOAC相关的ICH病例。与华法林相比，NOACs在发生CH的房颤患者中表现出较低的HE和死亡风险。 （Circ J 2015; 79：1018-1023）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号